Anti-inflammatory Action of Pterostilbene Is Mediated through the p38 Mitogen-Activated Protein Kinase Pathway in Colon Cancer Cells

Shiby Paul,1 Agnes M. Rimando,2 Hong Jin Lee,1 Yan Ji,1 Bandaru S. Reddy1 and Nanjoo Suh1,3

Abstract Oxidative/nitrosative stress and generation of proinflammatory cytokines are hallmarks of inflammation. Because chronic inflammation is implicated in several pathologic conditions in humans, including cancers of the colon, anti-inflammatory compounds may be useful chemopreventive agents against colon cancer. Stilbenes, such as resveratrol, have diverse pharmacologic activities, which include anti-inflammation, cancer prevention, a cholesterol-lowering effect, enhanced insulin sensitivity, and increased life span. We previously showed that pterostilbene (trans-3,5-dimethoxy-4′-hydroxystilbene), a structural analogue of resveratrol, is present in blueberries and that pterostilbene inhibited expression of certain inflammation-related genes in the colon and suppressed aberrant crypt foci formation in rats. Here, we examined molecular mechanisms of the action of pterostilbene in colon cancer. Pterostilbene reduced cell proliferation, down-regulated the expression of c-Myc and cyclin D1, and increased the level of cleaved poly(ADP-ribose) polymerase. A combination of cytokines (tumor necrosis factor-α, IFN-γ, and bacterial endotoxin lipopolysaccharide) induced inflammation-related genes such as inducible nitric oxide synthase and cyclooxygenase-2, which was significantly suppressed by treatment with pterostilbene. We further identified upstream signaling pathways contributing to the anti-inflammatory activity of pterostilbene by investigating multiple signaling pathways, including nuclear factor-κB, Janus-activated kinase–signal transducer and activator of transcription, extracellular signal-regulated kinase, p38, c-Jun NH2-terminal kinase, and phosphatidylinositol 3-kinase. Cytokine induction of the p38-activating transcription factor 2 pathway was markedly inhibited by pterostilbene among the different mediators of signaling evaluated. By silencing the expression of the p38α isoform, there was significant reduction in cytokine induction of inducible nitric oxide synthase and cyclooxygenase-2. Our data suggest that the p38 mitogen-activated protein kinase cascade is a key signal transduction pathway for eliciting the anti-inflammatory action of pterostilbene in cultured HT-29 colon cancer cells.

The intriguing link between chronic inflammation and cancer has been the subject of numerous studies for more than a century (1). In particular, the development of colon cancer is a characteristic scenario in which inflammatory conditions such as ulcerative colitis increase the risk of colon cancer by 20-fold (2). The presence of certain inflammation markers, such as the C-reactive protein circulating in the blood, is correlated with an increased risk of colon cancer (3). In addition, overexpression of proinflammatory enzymes, such as inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2), has been reported in human colon cancer (4, 5) and in an azoxymethane-induced colon cancer model in rats (6, 7). More importantly, selective inhibitors of these inflammatory genes are effective in reducing the number of colorectal polyps in humans and in suppressing the formation of azoxymethane-induced hyperplastic aberrant crypt foci and colon tumors in rats (7–10).

Epithelial cells express iNOS and COX-2 in response to inflammatory cytokines and the bacterial endotoxin lipopolysaccharide (LPS), and the transcriptional regulation of iNOS and COX-2 is complex (11–14). This process involves several transcription factors, including nuclear factor-κB (NF-κB), activator protein-1, CCAAT/enhancer binding protein, activating transcription factor (ATF)/cyclic AMP-responsive element binding protein, and Janus-activated kinase–signal transducer and activator of transcription (JAK-STAT) family (12, 14, 15). Depending on the cell type, various downstream
signaling pathways are also involved in the transcriptional regulation of iNOS and COX-2.

There are several upstream kinase pathways responsible for transcriptional regulation of COX-2 and iNOS, including mitogen-activated protein kinases (MAPK). MAPKs are composed of extracellular signal-regulated kinase (ERK), p38 kinase, and c-Jun NH2-terminal kinase (JNK; ref. 16). These MAPKs are activated by MAPK kinase (MAPKK), and once activated, these MAPKs in turn activate several transcription factors, such as Elk1, ATF2, and c-Jun, which are the major activators of iNOS and COX-2 genes (17, 18). It was reported that COX-2 expression induced by interleukin-1β (IL-1β) in HT-29 cells was up-regulated by all three MAPKs (19). Furthermore, p38 MAPK is the major signaling pathway, other than NF-κB, involved in the regulation of inflammatory cytokine synthesis (20).

Recently, we showed that pterostilbene (Fig. 1), a naturally occurring analogue of resveratrol, caused suppression of aberrant crypt foci formation in the azoxymethane-induced colon cancer model in rats, which may be due to a decreased expression of inflammatory genes, such as iNOS, in the colonic crypts and in the aberrant crypt foci (21). Stilbene derivatives, including resveratrol and pterostilbene, are present in small berries such as blueberries and dearberries (22, 23). The discovery of resveratrol as a cancer-preventive agent (24) has fostered interest in testing the cancer-preventive activity of other naturally occurring stilbenes in many laboratories (25–28). However, Riman et al. (33) have shown that pterostilbene, but not resveratrol, piceatannol, or resveratrol trimethyl ether, is a peroxisome proliferator-activated receptor α agonist, suggesting a difference in their mechanisms of action.

In the present study, we indicate that pterostilbene is more potent than resveratrol as an inhibitor of the proliferation of cultured HT-29 colon cancer cells. Although there have been some detailed studies on the chemopreventive effect of resveratrol, very little is known about the mechanism of action of pterostilbene. The present study aims to understand the inhibitory effects of pterostilbene on the induction of inflammatory markers in the HT-29 colon cancer cell line. Based on our studies, the anti-inflammatory property of pterostilbene may be regarded as a key attribute for its role against colon tumorigenesis. The effects of pterostilbene on the activation of upstream signaling pathways and transcription factors involved in NF-κB, JAK-STAT, and MAPK pathways were investigated. Among them, p38 MAPK was identified as a key mediator for the inhibitory effect of pterostilbene on the formation of iNOS and COX-2.

Fig. 1. Pterostilbene inhibits [3H]thymidine incorporation into the DNA of HT-29 cells and modulates the level of proteins involved in cellular proliferation and apoptosis. A, structure of pterostilbene. B, HT-29 cells were seeded on a 24-well plate (20,000 per well) in DMEM supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. The cells were incubated with pterostilbene at different concentrations or with DMSO as the control vehicle for 1, 2, or 3 d. Tritium-labeled thymidine (1 μCi; [3H]thymidine) per well was added and the amount of incorporated radioactivity in DNA was measured using a liquid scintillation spectrometer. The experiment was repeated twice, with each experiment done in duplicates. Points, mean; bars, SD. C, experiments were set up and conducted similar to the conditions as mentioned for B, with the exception that HT-29 cells were treated with pterostilbene, resveratrol, or DMSO as control for 3 d before [3H]thymidine incorporation. The experiment was repeated twice, with each experiment done in duplicates. Columns, mean; bars, SD. D, HT-29 cells (1.5 × 10⁶/100-mm dish) were treated with pterostilbene at a concentration of 50 μM/L. The cells were harvested after 9 or 18 h of incubation with pterostilbene, and protein samples were analyzed by Western blotting.
Materials and Methods

Reagents

Pterostilbene (trans-3,5-dimethoxy-4′-hydroxystilbene; Fig. 1) and resveratrol were synthesized at the Natural Products Utilization Research Unit, United States Department of Agriculture (purity >99.9%). The compounds were dissolved in DMSO, and the final concentration of DMSO in the cell culture studies was 0.1% or less. The controls were used DMSO alone in all experiments. Recombinant human IFN-γ and tumor necrosis factor-α (TNF-α) were purchased from R&D Systems, Inc., and LPS (from Escherichia coli 0111:B4 γ-irradiated) was purchased from Sigma.

Cell culture

Human colon carcinoma cell line HT-29 was obtained from the American Type Culture Collection. The cells were maintained in DMEM supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin at 37°C and 5% CO2. The cytokine mixture, consisting of 10 ng/mL TNF-α, IFN-γ, and LPS, was used to induce iNOS and COX-2, unless otherwise mentioned. The cells were treated with the test compound either alone or in combination with cytokines for different time intervals.

Measurement of cell proliferation by [3H]thymidine incorporation

HT-29 cells were plated at a density of 20,000 per well in a 24-well plate and treated with varying concentrations of pterostilbene for a period of 1, 2, or 3 d at 37°C. Before harvest, the cells were harvested for protein measurements after 15 h, and the samples were immunoblotted to determine induction of iNOS and COX-2.

Western blot analysis

Whole-cell and nuclear protein extracts from different experiments were collected and analyzed by Western blotting. The protein samples were separated on 4% to 15% SDS-PAGE gels (Bio-Rad) followed by transfer to a polyvinylidene difluoride membrane. The membranes were blocked with 5% milk in Tris buffer for 1 h and then incubated with the appropriate primary antibody solution overnight at 4°C. The membranes were washed with Tris buffer and incubated with horseradish peroxidase-conjugated secondary antibody solutions for 1 h at room temperature. The protein bands were visualized using a chemiluminescence-based kit from Amersham Biosciences. The primary antibodies against iNOS, COX-2, IκBα, p65, cyclin D1, c-Myc (Santa Cruz Biotechnology), phospho-STAT3 (p-STAT3), phospho-STAT1 (p-STAT1), phospho-ERK1/2 (p-ERK1/2), phospho-JNK1/2 (p-JNK1/2), p38 (p-p38), phospho-Akt (p-Akt), phospho-ATF2 (p-ATF2), phospho-Erk1 (p-Erk1), poly(ADP-ribose) polymerase (PARP), p38α, p38β, total p38 (Cell Signaling Technology, Inc.), and actin (Sigma) and secondary antibodies (Santa Cruz Biotechnology) were used.
Pterostilbene, Anti-inflammatory Action in Colon Cancer

**Quantitative reverse transcription-PCR analysis**

The procedure for quantitative reverse transcription-PCR (RT-PCR) analysis is previously reported (35). Briefly, the cells were incubated with compounds for indicated period and the cells were then lysed using Trizol to extract RNA. RNA was reverse transcribed into cDNA using a high-capacity cDNA archive kit (Applied Biosystems). The cDNA was used for quantitative PCR, which was run on the ABI Prism 700 Sequence Detection System. The primers for the iNOS, COX-2, IFN-γ, TNF-α, IL-1β, and glyceraldehyde-3-phosphate dehydrogenase were obtained from Applied Biosystems.

**Fluorescence microscopy**

HT-29 cells were incubated in a chamber slide (Nunc) with cytokines and pterostilbene for 15 and 30 min to detect p-p38 and p-ATF2, respectively. Cells were fixed with 4% paraformaldehyde [1× PBS (pH 7.4)] for 20 min and blocked with 10% bovine serum albumin/0.5% Triton X-100/1× PBS for 1 h. Following this, the cells were incubated sequentially with primary antibody (1:100 dilution for p-p38 or 1:25 dilution for p-ATF2) overnight and fluorophore-conjugated secondary antibody (Alexa Fluor 488, Invitrogen) for 1 h and 4',6-diamidino-2-phenylindole (DAPI) for 30 min. The cells were irradiated with green laser at 488 nm for detection of p-p38 and p-ATF2 and UV light at 364 nm for nuclear staining by DAPI.

**Small interfering RNA transfection study**

Small interfering RNA (siRNA) against p38α and p38β isoforms was purchased from Dharmacon. HT-29 cells were transfected as specified in the manufacturer’s protocol. Briefly, the cells were plated at 150,000 per well in six-well plates. Individual siRNA was mixed with Accell siRNA delivery medium and added to the wells to give a final concentration of 1 μmol/L per well. After incubation with the mixture for 72 h, the medium was changed to complete medium and cells were treated with cytokine mixture and pterostilbene for an additional 15 h. Changes in induction of iNOS and COX-2 were measured by Western blot analysis.

**Statistical analysis**

Quantitative data are reported as the mean ± SD for the individual experiments as specified in the figure legends. Statistical significance analysis was done using the Student’s t test. The number of observations for each treatment, represented as n, and the measure of significance of treatments, the P value, are given in the figure legends.

**Results**

**Pterostilbene inhibits the proliferation of cultured colon cancer HT-29 cells**

We evaluated the effect of pterostilbene and resveratrol on the growth of cultured colon cancer HT-29 cells. The cells were incubated with different concentrations of pterostilbene for 1, 2, and 3 days, and cell proliferation was estimated by measuring [3H]thymidine incorporated into DNA. The 3-day incubation gave the strongest growth inhibition, and there was a dose-dependent effect (Fig. 1B). As illustrated in Fig. 1C, pterostilbene was a more potent inhibitor of proliferation (IC50, 4.38 μmol/L) when compared with resveratrol treatment (IC50, 43.8 μmol/L) under the same conditions. IC50 values were determined using TableCurve 2D software (version 5.01) from Systat. To evaluate whether pterostilbene potentiates cell cycle arrest or apoptosis in HT-29 cells, we examined the effect of pterostilbene on proteins regulating the cell cycle/apoptosis pathways. Pterostilbene was effective in reducing c-Myc and cyclin D1 levels after a 9-hour incubation (Fig. 1C). However, pterostilbene showed no induction of p21 and p27, which belong to the CIP-KIP family of cyclin-dependent kinase inhibitors (data not shown). As a marker for the induction of apoptosis, we determined the level of cleaved PARP. Treatment with pterostilbene for 9 or 18 hours increased the level of cleaved PARP (Fig. 1D).

**Cytokines act synergistically to induce iNOS and COX-2 in HT-29 cells**

To determine which cytokines or the combination of cytokines that will give maximal induction of iNOS and COX-2 in HT-29 cells, we treated the cells with TNF-α, IFN-γ, LPS, and IL-1β either alone or in combination for 15 hours (Fig. 2A). Addition of the cytokines individually to HT-29 cells did not cause a noticeable induction of iNOS. Although the addition of IFN-γ plus LPS caused a strong induction, even stronger induction of iNOS among the combinations tested was exhibited by a triple combination of TNF-α, IFN-γ, and LPS. COX-2 was induced by TNF-α, LPS, or IL-1β individually, and TNF-α was the most potent inducer. The combination of TNF-α with either IL-1β or LPS yielded the strongest induction of COX-2.
The triple combination induced both iNOS and COX-2, and this combination was selected for additional studies. Because pterostilbene is a naturally occurring analogue of resveratrol, we first compared the inhibitory effects of pterostilbene and resveratrol against the induction of iNOS and COX-2 protein in this condition. At the concentration tested (30 μmol/L), pterostilbene showed better inhibitory activity than resveratrol against induction of iNOS and COX-2 proteins (Fig. 2B).

**Cytokine induction of iNOS and COX-2 is time dependent, and pterostilbene dose dependently blocks the induction**

To determine the kinetics of induction of iNOS and COX-2 in HT-29 colon cancer cells, the cells were treated with the cytokine mixture of TNF-α, IFN-γ, and LPS for periods of 9, 12, and 15 hours. The induction of iNOS was highest at 15 hours, whereas the COX-2 level was high at 9 to 12 hours and low at 15 hours (Fig. 2C). These data show that maximal induction of COX-2 occurs earlier than that of iNOS. As also shown in Fig. 2C, pterostilbene at 50 μmol/L markedly blocked the induction of iNOS and COX-2 by the cytokine mixture at each time point. In addition, we determined the effect of treatment of the cells with different concentrations of pterostilbene on the induction of iNOS and COX-2 by the cytokine mixture. Pterostilbene inhibited the induction of iNOS and COX-2 in a dose-dependent manner (Fig. 2D).

**Pterostilbene down-regulates mRNA levels of inflammatory genes iNOS and COX-2 and proinflammatory cytokines IL-1β and TNF-α**

The gene-mediated expression of iNOS and COX-2 is regulated both at the transcriptional and translational levels (13, 14). To evaluate the effect of pterostilbene on cytokine-induced expression of proinflammatory enzymes and cytokines, the induction of mRNA levels of iNOS, COX-2, IL-1β, IFN-γ, and TNF-α genes was analyzed by quantitative RT-PCR after HT-29 cells were treated with cytokines and/or pterostilbene. Pterostilbene at 30 μmol/L strongly inhibited iNOS, COX-2, and IL-1β mRNA induction by the cytokine mixture (Fig. 3). Induction of TNF-α mRNA by cytokines was observed, but pterostilbene showed only a weak inhibitory effect (Fig. 3). We also measured the mRNA level of IFN-γ induced by the cytokine mixtures, but it was too low to be detected in HT-29 cells (data not shown).

**Pterostilbene blocks the activation of p38 signaling in colon cancer cells**

Cytokines induce iNOS and COX-2 through various signaling pathways (13, 15). To elucidate the mechanism responsible for the anti-inflammatory action of pterostilbene, we examined the upstream pathways for iNOS and COX-2 formation, which are activated rapidly after cytokine treatment. As shown in Fig. 4A, the NF-κB/IκBα and JAK-STAT pathways were investigated. Cytokine treatment for a short time (15 minutes) decreased IκBα levels. Pterostilbene, however, did not block the degradation of IκBα protein induced by the cytokines (Fig. 4A). In addition, the accumulation of the p65 subunit of NF-κB in the nucleus was not affected by pterostilbene (data not shown), confirming that NF-κB signaling is not regulated by pterostilbene in colon cancer cells.

The significance of the JAK-STAT pathway in HT-29 cells was evaluated by the level of p-STAT1 and p-STAT3 proteins. Cytokines activated the STAT pathway, as shown by a strong induction of p-STAT1 and p-STAT3. However, pterostilbene did not alter the level of induced p-STAT1 and p-STAT3 (Fig. 4A). When we determined the activation of ERK1/2 and p38 kinases by cytokines by measuring the levels of phosphorylated ERK1/2 and p38, we found that pterostilbene did not block ERK1/2 activation but strongly inhibited activation of p38 (Fig. 4B). Cytokine-induced increase in p-JNK protein was noticeable, but there was little or no inhibitory effect of pterostilbene on this increase. Cytokine or pterostilbene treatment did not change the level of p-Akt, which is the downstream effector of the phosphatidylinositol 3-kinase pathway (Fig. 4B).

**The p38-ATF2 MAPK pathway is inhibited by pterostilbene in colon cancer cells**

Because pterostilbene is effective in down-regulating the cytokine-induced activation of p38, we further examined the involvement of pterostilbene on some of the known upstream effectors and downstream targets of p38 kinase. Phospho-MKK3/6 is known as the major molecule responsible for activating p38 MAPK, which, in turn, is activated by the upstream kinase in the MAPK cascade. We found that pterostilbene was effective in inhibiting cytokine-induced phosphorylation of MKK3/6 at 15 minutes (Fig. 5A). Furthermore, the activation (phosphorylation) of well-known downstream targets of p38, ATF2 and Elk1, was also blocked by pterostilbene at 30 minutes (Fig. 5B).

Changes in the intracellular expression pattern of p-p38 and p-AKT2 were detected by immunofluorescence. With regard to p-p38, cytokine treatment induced p-p38 and its localization mainly in the nucleus and perinuclear region. Recently, Siddiqui et al. (36) have reported similar localization pattern for activated p38 in endothelial cells. Pterostilbene treatment attenuated this increase (Fig. 5C), parallel to the observations from Western blot analysis (Fig. 4B). Activated transcription factor p-STAT1 and p-STAT3. However, pterostilbene effectively blocks activation of p38 MAPK signaling. HT-29 cells (1.5 × 10^6/100-mm dish) were incubated with a mixture of TNF-α, IFN-γ, and LPS (each at 10 ng/mL) and pterostilbene (30 μmol/L) for 15 min. The cells were harvested and protein samples were immunoblotted for IκBα, p-STAT3, p-STAT1, p-ERK1/2, p-p38, p-JNK1/2, p-Akt, and β-actin.

Fig. 4. Evaluation of different cellular signaling pathways affected by pterostilbene in HT-29 cells. A, pterostilbene showed little or no effects on the NF-κB and JAK-STAT pathways, B, pterostilbene effectively blocks activation of p38 MAPK signaling. HT-29 cells (1.5 × 10^6/100-mm dish) were incubated with a mixture of TNF-α, IFN-γ, and LPS (each at 10 ng/mL) and pterostilbene (30 μmol/L) for 15 min. The cells were harvested and protein samples were immunoblotted for IκBα, p-STAT3, p-STAT1, p-ERK1/2, p-p38, p-JNK1/2, p-Akt, and β-actin.
factor, p-ATF2, was prominent in the nucleus by cytokine treatment and pterostilbene virtually nullified these elevated levels (Fig. 5D). Thus, significantly lower levels of the activated p38 and ATF2 were observed in the nucleus of HT-29 cells after treatment with the stilbene.

**p38α isoform is crucial for the induction of iNOS and COX-2 in HT-29 colon cancer cells by the cytokine mixture**

Four mammalian p38 isoforms, p38α, p38β, p38γ, and p38δ, have been identified: p38α and p38β forms are ubiquitously expressed, whereas p38γ is present mostly in skeletal muscle, heart, lung, and thymus, and p38δ in lungs, pancreas, testis, kidney, and small intestine (37). SB203580, a pharmacologic inhibitor that specifically targets the p38α and p38δ isoforms (38), was shown to lower cytokine induction of iNOS and COX-2 in our study (data not shown). Thus, to delineate the role of different isoforms of p38 MAPK for the induction of iNOS and COX-2, we used siRNA against p38α and p38β. Results showed that absence of p38α expression almost completely blocked the induction of iNOS (Fig. 6). Because deletion of p38α expression by itself resulted in almost no induction of iNOS, there was hardly any change by cotreatment of pterostilbene with the cytokine mixture in the p38α siRNA-treated group. In addition, siRNA against p38α also markedly reduced COX-2 induction. Moreover, p38α is the most abundant isoform of p38 (Fig. 6, total p38 blot). These results suggest that p38α is the key molecule in inducing iNOS and COX-2 with the cytokine mixture, and pterostilbene may be acting through this p38α isoform to block the inflammatory enzyme expression in HT-29 cells.

**Discussion**

In the present study, we investigated the mechanisms of action of pterostilbene in HT-29 colon cancer cells. The results of our study indicate that pterostilbene is more effective than resveratrol as an inhibitor of DNA synthesis in the human adenocarcinoma HT-29 cell line (Fig. 1C). In addition, pterostilbene showed better activity than resveratrol for inhibiting the induction of inflammatory genes, such as...
as iNOS and COX-2 (Fig. 2B). The better activity of pterostilbene over resveratrol may, in part, be explained by structural differences. Pterostilbene with two methoxy groups and one hydroxyl group has improved lipophilicity and a better potential for cellular uptake compared with resveratrol, which has trihydroxy groups. We showed that pterostilbene inhibited the growth of HT-29 cells and altered markers of cellular proliferation and apoptosis, as shown by lower protein levels of c-Myc and cyclin D1 as well as an increased level of cleaved PARP in pterostilbene-treated cells (Fig. 1). These data are consistent with the results of recent studies indicating that pterostilbene and resveratrol induce apoptosis and down-regulate genes that are directly involved in cell proliferation, including cyclin D1, in vivo and in vitro (39, 40).

In our study with HT-29 colon cancer cells, a triple combination of TNF-α, IFN-γ, and LPS resulted in a marked induction of iNOS and COX-2 (Fig. 2A), and pterostilbene reduced the induction of iNOS and COX-2 in a dose-dependent fashion (Fig. 2D). Quantitative RT-PCR data showed that the regulation of iNOS and COX-2 occurred at the transcriptional level with pterostilbene effectively down-regulating the cytokine induction of iNOS and COX-2 mRNA (Fig. 3). Treatment with a mixture of cytokines induced mRNA synthesis for proinflammatory cytokines, such as IL-1β, and this was significantly inhibited by pterostilbene. These results underscore the anti-inflammatory potential of pterostilbene.

TNF-α, IFN-γ, IL-1β, and LPS are effective inducers of the expression of inflammatory genes in macrophages and epithelial cells, although expression levels vary with cell type (41). The up-regulation of iNOS and COX-2 is mediated by multiple pathways, which vary with cell type and cytokines used. The involvement of NF-κB, activator protein-1, MAPKs, and JAK-STAT in the expression of these genes has been evaluated for a variety of compounds with anti-inflammatory potential. Resveratrol, which is structurally similar to pterostilbene, reduced iNOS and COX-2 induction in rat glioma cells and inhibited iNOS induction by LPS in macrophages by reducing NF-κB (42, 43). Recently, pterostilbene was found to suppress the activation of ERK, p38, phosphatidylinositol 3-kinase, and NF-κB in LPS-induced murine macrophages, suggesting that these pathways play crucial roles in the action of pterostilbene to inhibit iNOS and COX-2 in macrophages (44). However, our results show the p38 MAPK cascade as a major signaling pathway inhibited by pterostilbene in HT-29 colon cancer cells, suggesting that cell type specificity may contribute to this difference (Fig. 4). In addition, our preliminary data revealed that pterostilbene does not affect cell proliferation-related events via the p38 pathway (data not shown), indicating that there may be two distinct mechanisms of pterostilbene for its antiproliferation and anti-inflammatory actions.

The p38 MAPK cascade is activated by its upstream kinase MKK3/6, which is the MAPKK for p38, and we found that pterostilbene strongly inhibited the activation of both MKK3/6 and p38 (Fig. 5A and B). This suggests that pterostilbene may activate p38 MAPK through the conventional kinase cascade that has small GTP proteins, such as Rac, Rho, cdc42, and MAPKs that activate MAPKKs. Alternatively, pterostilbene may activate p38 MAPK through an alternative kinase cascade that has smaller GTP proteins, such as Rac, Rho, cdc42, and MAPKK. This alternative cascade is followed by phosphorylation and nuclear translocation of p38 and p65 (45). In the MAPK cascade, we also observed that pterostilbene acts on downstream targets of p38, namely, ATF2 and Elk1 (Fig. 5B). There are a myriad of transcription factors and kinases that are affected by p38, such as MEF2, MSK, CHOP, and MAPKAP (46), but we examined two key mediators, ATF2 and Elk1, which are known to play important roles in inflammatory gene responses (47). ATF2 is a subunit of the activator protein-1 complex and binds to the CRE promoter sequence on iNOS and COX-2, and Elk1 belongs to the ETS transcription factor and binds to the ETS DNA-binding domain on the promoter sequence of inflammatory genes (14).

In the present study, we found that pterostilbene blocked the phosphorylation and nuclear translocation of p38 and ATF2 induced by cytokine mixture (Fig. 5B-D), providing evidence for the involvement of the p38 MAPK-ATF2 pathway for the anti-inflammatory action of pterostilbene in HT-29 colon cancer cells.

Among the different isoforms of p38 MAPKs, p38α is known to play a key role in inflammatory processes (48). This MAPK was originally identified as a molecular target of the pyridinyl imidazole class of compounds, such as SB203580, which were known to inhibit proinflammatory cytokine synthesis, and many of these inhibitors have entered clinical trials for inflammatory diseases (38). Because the p38 inhibitor SB203580 suppresses activation of both p38α and p38β, it is difficult to distinguish the effects produced by each isoform independently. In our study, we used RNA interference to show that p38α is the most abundant isoform in HT-29 colon cancer cells, and p38α is the key molecule involved in iNOS and COX-2 expression (Fig. 6). This observation along with coordinated results from short time point experiments (Figs. 4 and 5) indicate that pterostilbene may inhibit iNOS and COX-2 expression primarily through its action on p38α MAPK.
In conclusion, the data presented here indicate that pterostilbene inhibits growth and exerts an anti-inflammatory action in HT-29 colon cancer cells. Pterostilbene-induced inhibition of p38 MAPK signaling may be a key effect of pterostilbene required for reduction of inflammatory markers, such as iNOS and COX-2. Overall, pterostilbene is a promising anti-inflammatory agent for inhibition of colon carcinogenesis.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Acknowledgments
We thank the Department of Chemical Biology for their technical assistance and Dr. Allan Conney for helpful comments on our manuscript.

References
Anti-inflammatory Action of Pterostilbene Is Mediated through the p38 Mitogen-Activated Protein Kinase Pathway in Colon Cancer Cells

Shiby Paul, Agnes M. Rimando, Hong Jin Lee, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/1940-6207.CAPR-08-0224

Cited articles
This article cites 47 articles, 16 of which you can access for free at:
http://cancerpreventionresearch.aacrjournals.org/content/2/7/650.full.html#ref-list-1

Citing articles
This article has been cited by 5 HighWire-hosted articles. Access the articles at:
/content/2/7/650.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.